Dechra Pharmaceuticals PLC Additional Listing (9592G)
April 01 2022 - 5:56AM
UK Regulatory
TIDMDPH
RNS Number : 9592G
Dechra Pharmaceuticals PLC
01 April 2022
1 April 2022
Dechra(R) Pharmaceuticals PLC
(Dechra or the Company)
Additional Listing
An application for admission to the Premium Segment of the
Official List has been made to the Financial Conduct Authority and
the London Stock Exchange for the following:
-- Additional 2,261 for the Save As You Earn (SAYE) Scheme block listing;
-- Additional 150,000 for the 2017 Long Term Incentive Plan block listing;
-- Additional 80,000 for the Global Save As You Earn 2018 block listing.
These Shares will rank pari passu with the Company's existing
shares in issue. It is expected that admission will become
effective on or around 7 April 2022 .
For further information, please contact:
Dechra Pharmaceuticals PLC
Melanie Hall, Company Secretary
Telephone number: +44 (0) 1606 814730
Email: corporate.enquiries@dechra.com
About Dechra
Dechra is a global veterinary pharmaceuticals and related
products business. Our expertise is in the development,
manufacture, and sales and marketing of high quality products
exclusively for veterinarians worldwide. The majority of Dechra's
products are focused on key therapeutic categories where we have
leading market positions, and many of our products are used to
treat medical conditions for which there is no other effective
solution or have a clinical or dosing advantage over competitor
products. For more information, please visit: www.dechra.com .
Trademarks
Trademarks appear throughout this document in italics. Dechra
and the Dechra "D" logo are registered trademarks of Dechra
Pharmaceuticals PLC.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ALSUPUAACUPPUBG
(END) Dow Jones Newswires
April 01, 2022 05:56 ET (09:56 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Apr 2023 to Apr 2024